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Abstract. P2Y12 is a platelet receptor that is involved in ADP signal transduction and is an attractive target for antithrombotic drugs. The side effects of 
antithrombotic drugs are not pleasant for the patient, so research into the 
development of new antithrombotic agents is still necessary. Evaluation of 
absorption, distribution, metabolism, elimination, and the toxicity profile of 
candidate drugs is an important step in drug development. The aim of this study 
was to predict the potency of ferulic acid (FA) and its derivatives (FA1-24) as 
antiplatelet drugs by a docking study on the P2Y12 receptor (PDB ID: 4PXZ) and their ADMET performance. The docking study was performed using Molegro 
Virtual Docker, version 5.5. ADMET prediction of FA was conducted using the 
pkCSM online tool. The results of the in silico study showed that FA-19 had the 
lowest MolDock score (MDS), which means that this compound is predicted to 
have the greatest activity. FA-19 is also predicted to be practically non-toxic. It 
is expected that FA-19 will have good intestinal absorption and is similarly 
distributed in the intestine and in the blood plasma. Its penetration in the blood-
brain barrier is moderate but does not inhibit the CYP2D6 and CYP3A4 
enzymes. 
Keywords: ADMET prediction; antiplatelet; ferulic acid; molecular docking, P2Y12 
receptor. 
1 Introduction 
Cardiovascular diseases and strokes are major problems of morbidity and 
mortality in many countries, including Indonesia. In Indonesia, the prevalence 
of heart and blood vessel diseases continuously increases and the prevalence of 
coronary heart disease (CHD) in 2013 was 0.5%. Deaths caused by 
cardiovascular diseases, especially CHD and strokes, are predicted to increase 
up to 23.3 million by 2030 [1]. 
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P2Y12 receptors play an important role in thrombus formation, i.e. in ADP 
signal transduction, and are an attractive target for antithrombotic drugs such as 
Prasugrel and Cangrelor [2-4]. The P2Y12 receptor can be used as a therapeutic 
target and can be applied to molecular modeling and structure-activity 
relationship based drug design [5]. Unfortunately, the current antithrombotic 
drugs possess undesired side effects, such as bleeding and hemostasis problems. 
Therefore, research on drug design of new antiplatelet agents is important [6]. 
Drug design is an attempt to improve existing drugs or compounds with specific 
pharmacological activity and is often described as a systematic elaboration 
process with the aim of obtaining new drugs with better activity and reducing 
any side effects that exist through molecular manipulation. The structural 
changes of a compound will alter the physicochemical properties of the 
compound, including its lipophilic, electronic and steric properties, which may 
cause changes in its biological activity [7,8]. 
One of the cinnamic acid derivatives, i.e. (E)-3-(4-hydroxy-2-methoxyphenyl) 
propenoic acid or ferulic acid (FA3), has been reported as an inhibitor of 
platelet aggregation through in vitro assay [9]. The mechanisms of ferulic acid 
in preventing platelet aggregation are: (1) inhibiting the [Ca2+] channel on the 
cell membrane surface and interfering with phospholipase C in releasing [Ca2+] 
to reduce the combination of ADP with P2Y12; and (2) inhibiting the synthesis 
of TXA2, which can bind to TXA2R to activate platelets [10]. In an effort to 
obtain an effective and safe anti-platelet compound, an in silico assay of FA 
derivatives (FA1-24) was observed through a docking study on the P2Y12 
receptor (PDB ID: 4PXZ).  
An in silico assay is conducted by docking a molecule to predict its activity 
with the selected target cell. Docking is an attempt to harmonize the ligand, a 
small molecule inside the target cell, which is a large protein molecule [11]. The 
results of the in silico test are in the form of bond energy values, or the Moldock 
score (MDS). The bond energy indicates the amount of energy required to form 
a bond between the ligand and the receptor. The lower the bonding energy, the 
more stable the bond. If the ligand bond with the receptor is stable, it can be 
predicted that the activity will be stronger [12].  
Besides measuring docking activity, one of the principle stages in drug design is 
the evaluation of the pharmacokinetic properties, i.e. the absorption, 
distribution, metabolism, elimination, and toxicity (ADMET), of the candidate 
drug [13]. ADMET analysis using an animal model is expensive, so we used 
molecular modeling in an effort to predict the chemical properties of the 
molecular chemistry, the pharmacokinetic properties (ADME), and the toxicity 
of the compounds [13,14]. 
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2 Material and Method 
2.1 Receptor  
The molecular structure of P2Y12 receptors can be downloaded via a protein 
data bank site [15]. The P2Y12 receptor with PDB ID: 4PXZ was selected, 
which contains a ligand (5-(6-amino-2-(methylthio)-9H-purine-9-yl) -3,4-
dihydroxyte - trahydrofuran-2-yl)-methyl diphosphate code 6AD_1201[A]. 
2.2 Ligand 
The structure of the ligands (FA1-24) was drawn using the 2D/3D ChemBio 
Draw Ultra software application, version 12 (Cambridge Soft) and then copied 
into the ChemBio 3D Ultra software application, version 12, to create the 3D 
structure and measure its minimum energy using MMFF94. This was then 
stored as mol2 {SYBYL2 (*.Mol2)}.  
2.3 Validation of Docking Study 
The validation of the docking study was performed by re-docking the ligand 
reference into an appropriate protein cavity. Re-docking is accepted if the root 
mean square value (RMSD) < 2.0 Aº. 
2.4 Docking Study 
The docking study of these compounds on the P2Y12 receptor (4PXZ) was 
conducted using Molegro Virtual Docker, version 5.5. (Molegro ApS). The best 
docking results can be detected visually by comparing the structure of the 
docked molecules with the crystal structure of the reference ligand (6AD_1202 
[A]) in the binding site. The results are presented as MolDock scores (Figure 1). 
The lowest energy indicates the best binding pose between the functional group 
of the ligand and the amino acid residue of the protein. The ligand-protein 
complexes with the lowest MDS were used for further visual examination 
(Figures 2-6).  
2.5 Prediction of ADME and Toxicity of Compounds 
Prediction of the pharmacokinetic properties (ADME: absorption, distribution, 
metabolism, and excretion) and toxicity of the FA derivatives was performed 
using the pkCSM online tool, i.e. firstly the tested compounds and the 
comparative compound were drawn as 2D molecular structures with ChemBio 
Draw Ultra and copied into ChemBio 3D Ultra to create a 3D structure, and 
then stored as * .sdf file or * .pdb files. Secondly, all of the tested compounds 
and the comparative compound were translated into SMILES format using 
SMILES Translator Online Help [16]. In the SMILES format, the compounds 
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were processed using the pkCSM online tool [17] to predict the ADME and the 
toxicity of the compounds. Also, the ProTox online tool [18] was used to 
predict oral rodent toxicity by determining the LD50 value and the classification 
of compound toxicity based on the Globally Harmonized System (GSH). 
3 Results and Discussion 
3.1 Docking Study 
Molecular docking was carried out to elevate and develop the pharmacological 
activity of the FA derivatives. To explain the mode of binding between the FA 
derivatives and human P2Y12 receptor, docking studies were performed using 
the X-ray crystal structure of human P2Y12 in complex with its full agonist onto 
PDB ID: 4PXZ.  
The MolDock score is a differential evolution algorithm in the Molegro Virtual 
Docker program. The MDS, or Escore, is the sum of Einter and Eintra by Eq. (1), 
Einter is estimated by Eq. (2) and Eintra is estimated by Eq. (3).  
 𝐸௦௖௢௥௘ ൌ  𝐸௜௡௧௘௥ ൅ 𝐸௜௡௧௥௔  (1) 
 𝐸௜௡௧௘௥ ൌ  ∑ ∑ ൤𝐸௉௅௉൫𝑟௜௝൯ ൅ 332.0 ௤೔௤ೕସ௥೔ೕమ൨௝ୀ௣௥௢௧௘௜௡௜ୀ௟௜௚௔௡ௗ  (2) 
 𝐸௜௡௧௥௔ ൌ  ∑ ∑ ൣ𝐸௉௅௉൫𝑟௜௝൯൧௝ୀ௣௥௢௧௘௜௡௜ୀ௟௜௚௔௡ௗ   
 ൅ ∑ 𝐴 ሾ1 െ cos ሺ𝑚𝜃 െ 𝜃௢ሻሿ  ൅  𝐸௖௟௔௦௛௙௟௘௫௜௕௟௘ ௕௢௡ௗ   (3) 
Einter is the ligand-receptor interaction energy, while Eintra is the internal energy 
of the ligand. EPLP is calculated by two different parameters, i.e. the van der 
Waals interaction and the electrostatic interactions [19]. 
The MDS of the FA derivatives (FA1-24) can be seen in Figure 1. The MDS of 
the reference ligand (5-(6-amino-2-(methylthio)-9H-purine-9-yl)-3,4-
dihydroxytetrahydrofuran-2-yl)-methyldiphosphate, code 6AD_1202[A] 
is -187.880 kcal/mol, while its RMSD value is 1.87 A.  
Based on the data presented in Figure 1, all FA derivatives (FA4-24) apart from 
FA1 and FA2 have an MDS value lower than FA3 (ferulic acid), as is generally 
known. The structure modification of FA3 to FA2 through the demethylation of 
the methoxy moiety of FA3 to the hydroxyl moiety of FA2 decreased the molar 
refractivity (MR) and the MDS. The structure modification of FA3 to FA1 
through hydrogenation of the vinylic double bond of FA3 also decreased the 
MDS. Therefore, it is concluded that the methoxy and the vinylic double bond 
are important moieties interacting with the P2Y12 receptor. 
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Structure modification of the phenolic group of FA3 with the benzoyl- and 
substituted-benzoyl moieties (FA16-19) leads to different three-dimensional 
(3D) shapes of the compounds, so their interactions with the receptor are more 
effective, especially the steric interactions. Molecule FA19 ((E)-3-(3-methoxy-
4-((4-methoxybenzoyl)oxy)phenyl)acrylic acid) had the lowest MDS, 
i.e. -159.804 kcal/mol, while molecule FA3 had MDS -111.140 kcal/mol.  
Compound FA19 had the highest PSA (A2) value (Table 2) among the other 
derivatives, enabling greater receptor interaction. Therefore, it can be predicted 
that the bond between molecule FA19 and the P2Y12 receptor as the target 
protein is more stable than for FA3. This bond is the strongest among the other 
derivatives. 
 
Figure 1 Barchart of the MolDock Score (MDS) of FA derivatives (FA1-24) by 
Molegro Virtual Docker. PDB ID: 4PXZ (x = MDS; y = sample). 
The P2Y12 receptor responds to the ADP signal and participates in the inhibition 
of adenyl cyclase, Ca2+-dependent cell migration, regulation of cell 
morphology, and cellular aggregation. P2Y12 must be stimulated for ADP-
induced platelet aggregation to occur, which can be prevented by a substance 
that impartially inhibits the receptor. P2Y12 has a specific tissue distribution, 
making it an important target for therapeutic intervention [2] so that the 
compound binding to the receptor will inhibit P2Y12 activity in platelet 
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aggregation. The best docking position in the 3D structure molecules of 
6AD_1201[A]-FA3-FA19 can be seen in Figure. 2.  
 
Figure 2 The binding mode of compound 6AD_1201[A], FA3 and FA19 to the 
P2Y12 receptor. (A) The best docking position of the 3D structures of 6AD_1201[A] (green), FA3 (yellow), FA19 (blue) in stick style; residue amino 
acids are shown as lines and ligands are represented by thick lines with a fixed 
color. (B) The best docking position of 6AD_1201[A] (green), FA3 (yellow), 
FA19 (blue) with P2Y12 represented as a red ribbon. 
The docking study was carried out at cavity 2; Vol. 74.752; surface: 264.56. 
The interactions of each molecule, i.e. 6AD_1201[A], FA3 and FA19, are 
displayed in Figures 3-5. 
 
Figure 3 The interaction of the functional groups of molecule 6AD_1201[A] 
with the P2Y12 receptor (PDB ID: 4PXZ) in 2D form. The blue line represents the hydrogen bonding interaction and the red line represents the steric 
interaction. 
In Figure 3, the interaction between molecule 6AD_1201[A] and the P2Y12 
receptor can be seen. Hydrogen bonding interaction occurs between the 
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phosphate groups of molecule 6AD_1201[A] and the amino acid residues, i.e. 
Arg93, Cys97, Ser101, Tyr105, Thr163, Cys175, His187, Lys280, Arg256, 
Tyr259. In addition, steric interactions of the adenosine moiety take place with 
the residues Asn191 and Val190.  
 
Figure 4 Interaction of the functional groups of molecule FA3 with the P2Y12 receptor (PDB ID: 4PXZ) in 2D form (A) and 3D form (B). The blue line 
represents the hydrogen bonding interaction and the red line represents the steric 
interaction. The residue amino acids are shown as thin lines and the ligand is 
shown as a thick line with a fixed color.  
According to Figure 4, the molecule FA3 compound has three hydrogen bonds 
with Hys187, Lys179, Ser156, Asn191 and Cys194. In addition, FA3 also has 
steric interaction with amino acid residues of the P2Y12 receptor, i.e. Val102, 
Tyr105, Tyr109, Ser156, Asn159, Val190.  
 
Figure 5 The interaction of the functional groups of molecule FA19 with the 
P2Y12 receptor (PDB ID: 4PXZ) in 2D form (A) and 3D form (B). The residue amino acids are shown as thin lines and the ligand is shown as a thick line with a 
fixed color. The blue lines represent hydrogen bonding interaction and red lines 
represent steric interactions. 
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Based on Figure 5, there was a modification in the phenolic moiety of FA3 into 
the p-methoxybenzoyl moiety of FA19. This modification led to an increase of 
the interaction between the FA19 molecule and the amino acid residues in the 
P2Y12 receptor. The carboxylate group of FA19 molecules has hydrogen bonds 
with the residues Val102, Ser101, and Phe106. In addition, the methoxy group 
posseses hydrogen bonds with residue Thr260. The p-methoxybenzoyloxy-
moiety of FA19 has hydrogen bonding with Tyr109. The FA19 molecule has 
steric interaction with Tyr105, Ser156, Leu154, Pro158, Asn159, Trp186, 
Val190, Asn191, and Arg256 residues of the P2Y12 receptor. Besides hydrogen 
bonding interaction, the p-methoxybenzoyl-moiety of FA19 also contributes to 
hydrophobic interaction with Asn191, Tyr105, and Arg256, thus enhancing the 
interaction with that receptor.  
 
These docking studies suggest that FA3 and FA19 have a distinct binding pose 
with 6AD_1201[A] as ligand reference, except Tyr105, Val190 and Arg256. 
The P2Y12 receptor antagonist, i.e. 2-MeSADP, has hydrophobic interactions 
with the Tyr105, Val190, and Leu155 residues, i.e. the same as FA3 and FA19 
[2]. 
3.2 ADMET Profiles 
Chemical databases contain hundreds of thousands of molecules that could be 
suitable ligands for a receptor. But, no matter how good the fit with the 
receptor, the candidate molecule is of no use if the absorption is poor or if the 
drug is excreted too slowly from the body. 2245 drugs from the World Drugs 
Index database were analyzed and it was concluded that a compound is more 
likely to have poor absorption or permeability if: the molecular weight exceeds 
500; the calculated octanol/water partition coefficient (log P) exceeds +5; there 
are more than 5 H-bond donors (HBD) expressed as the sum of O–H and N–H 
groups; and there are more than 10 H-bond acceptors (HBA) expressed as the 
sum of N and O atoms. The above analysis is called the Lipinski Rules of Five 
because all values are multiples of five [20].  
The results of the in silico study of the physicochemical properties of the FA 
derivatives can be seen in Table 1. Based on Table 1, it can be seen that the 
molecular weight values of the ferulic acid derivatives (FA1-24) ranged from 
180.159 to 332.739 (<500), the value of log of the octanol/water partition 
coefficient (log P) ranged from 1.20 to 3.67 (< 5), the amount of HBD ranged 
from 3 to 5 (≤ 5), and the amount of HBA ranged from 1 to 3 (< 10). This 
means that all derivatives meet the Lipinski Rules of Five [20]. Hence, it can be 
predicted that these FA derivative compounds will be easily absorbed and have 
high permeability. 
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Table 2 ADMET properties of FA derivatives by ProTox Online Tool. 
Code 
Absorbtion Distribution Metabolism Excre tion Toxicity 
Intestin
al abs. 
Skin 
Permea
bility 
Caco-2 
permeab
ility 
VDss 
BBB 
permea
bility 
CNS 
Permea
bility 
CYP 
2D6 
inhibit
or 
CYP 
3A4 
inhibi 
tor 
Total 
Clearance 
Ames 
Toxic
ity 
Hepato
toxicity 
LD50 
(mg/kg) Class
FA1 93.921 -2.881 0.279 -0.851 -0.242 -2.573 no no 0.621 no no 2000 4 
FA2 97.322 -2.992 1.253 -0.457 -0.025 -2.493 no no 0.636 yes no 2980 5 
FA3 96.903 -2.961 1.275 -0.392 -0.010 -2.501 no no 0.666 yes no 1772 4 
FA4 96.483 -2.901 1.300 -0.335 -0.005 -2.497 no no 0.679 yes no 1772 4 
FA5 96.064 -2.852 1.325 -0.276 -0.021 -2.493 no no 0.695 no no 1772 4 
FA6 95.645 -2.814 1.415 -0.217 -0.036 -2.490 no no 0.714 no no 7900 6 
FA7 100.00 -2.678 1.298 -0.409 -0.129 -1.671 no no 0.721 no no 9600 6 
FA8 96.937 -2.876 0.376 -0.994 -0.366 -2.639 no no 0.718 no no 9600 6 
FA9 96.518 -2.845 0.944 -0.942 -0.391 -2.635 no no 0.745 yes no 1772 4 
FA10 96.099 -2.818 0.943 -0.887 -0.415 -2.631 no no 0.762 yes no 3450 5 
FA11 95.680 -2.795 0.942 -0.829 -0.439 -2.627 no no 0.781 no no 1772 4 
FA12 95.261 -2.776 0.942 -0.768 -0.463 -2.624 no no 0.800 no no 1772 4 
FA13 96.301 -2.830 1.036 -1.066 -0.350 -2.293 no no 0.655 yes no 1772 4 
FA14 94.641 -2.826 1.019 -1.099 -0.543 -2.178 no no 0.070 no no 3450 5 
FA15 96.099 -2.831 1.041 -1.034 -0.343 -2.218 no no 0.658 no no 3450 5 
FA16 96.298 -2.866 1.053 -1.186 -0.603 -2.914 no no 0.610 no no 3450 5 
FA17 94.928 -2.949 1.214 -0.082 -0.007 -2.578 no no 0.396 no no 3450 5 
FA18 94.509 -2.934 1.235 -0.018 -0.023 -2.586 no no 0.481 no no 3450 5 
FA19 94.089 -2.906 1.260 -0.037 -0.038 -2.582 no no 0.696 no no 3450 5 
FA20 96.601 -2.843 1.312 -0.809 0.015 -2.132 no no 0.519 no no 300 3 
FA21 96.398 -2.846 1.333 -0.777 0.027 -2.057 no no 0.520 no yes 300 3 
FA22 60.253 -2.979 0.228 -0.883 -0.732 -2.599 no no 0.537 no no 300 3 
FA23 97.073 -2.931 0.421 -1.173 -0.600 -3.177 no no 0.715 yes no 500 4 
FA24 94.109 -2.878 0.325 -0.815 -0.230 -2.689 no no 0.321 no no 500 4 
Skin permeability is an important consideration for improving drug efficacy that 
is particularly of interest in the development of transdermal drug delivery. A 
molecule will barely penetrate the skin if log Kp is more than -2.5 cm/h [21]. 
From Table 2 it can be seen that the skin permeability (Kp) of ferulic acid 
derivatives ranges from -2.678 to -2.992 cm/h (< -2.5). Therefore, it can be 
predicted that all derivatives have good skin penetrability.  
The Caco-2 cell line is composed of human epithelial colorectal 
adenocarcinoma cells. The Caco-2 monolayer of cells is widely used as an in 
vitro model of the human intestinal mucosa to predict the absorption of orally 
administered drugs by measuring the log of the evident permeability coefficient 
(log Papp; log cm/s). A compound is considered to have a high Caco-2 
permeability if it has Papp > 8 x 106 cm/s. For the pkCSM predictive model, 
high Caco-2 permeability is translated into predicted log Papp values > 0.90 
cm/s [21]. 
From Table 2 it can be seen that the Caco-2 permeability value (log Papp) of the 
ferulic acid derivatives ranges from 0.228 to 1.415 cm/s, and there are 19 
compounds with log Papp > 0.9 cm/s, so it can be predicted that the compounds 
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have a high Caco-2 permeability. Five FA derivatives, FA1, FA8, FA22, FA23, 
and FA24, have log Papp < 0.9 cm/s, so it is predicted that these compounds 
have low Caco-2 permeability. 
The volume of distribution (VD) is the calculated volume that the whole 
quantity of a medicine will be circulated at an equal level of blood plasma. The 
higher the VD is, the larger the amount of a drug is distributed to tissue rather 
than plasma. This model is established from the estimation of the steady-state 
volume of distribution (VDss), which is then revealed as log L/kg. According to 
Pires et al. [21], VDss higher than 2.81 L/kg (log VDss > 0.45) is categorized as 
high, whereas VDss lower than 0.71 L/kg (log VDss < -0.15) is categorized as 
low [12]. From Table 3 it can be seen that the VDss values of the FA 
derivatives range from -1.186 to 0.037, and three compounds have a VDss value 
of < -0.15, i.e. FA18, FA19, and FA20, so it can be predicted that almost all 
derivatives of these compounds can be distributed evenly providing an equal 
level of blood plasma.  
The blood-brain barrier (BBB) secures the brain from exogenous compounds. 
The ability of a drug to cross into the brain is an important parameter to 
consider for reducing side effects and toxicities or to improve the efficacy of 
drugs whose pharmacological activity is within the brain. The permeability of 
the blood-brain barrier is calculated in vivo as log BB, the logarithmic ratio of 
the brain-to-plasma drug concentration. Molecules are able to pass through the 
blood brain barrier promptly when log BB is higher than 0.3, but compounds 
with log BB smaller than -1 barely reach the brain [21]. From Table 2 it can be 
seen that the ranges of log BB value of the FA derivatives range from -0.732 to 
0.129, which means greater than -1, so it can be predicted that all the derivatives 
are able to penetrate the blood-brain barrier moderately. 
The permeability of the blood-surface area of the central nervous system (CNS) 
permeability (log PS) is a direct measurement that can be obtained from in situ 
brain perfusions with the compound directly injected into the carotid artery. 
This lacks systemic distribution effects that may distort brain penetration [21]. 
Compounds with log PS > -2 are considered to be able to penetrate the CNS, 
while those with log PS < -3 are considered to be unable to penetrate the CNS 
[21]. From Table 2 it can be seen that the log PS values of the FA derivatives 
range from -1.671 to -3.177. There is one compound (FA7, log PS = -1.617) 
capable of penetrating the CNS, one compound (FA23, Log PS = -3.177) that is 
unable to penetrate the CNS, while the other derivatives are able to penetrate the 
CNS moderately. 
Cytochrome P450 is an important detoxification enzyme in the body, mainly 
found in the liver. It oxidizes xenobiotics to facilitate their excretion. Many 
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drugs are deactivated by cytochrome P450’s but some can be activated by it. 
Inhibitors of this enzyme, such as grapefruit juice, can affect drug metabolism 
and are contraindicated. The cytochrome P450’s are responsible for the 
metabolism of many drugs. However, inhibitors of the P450’s can dramatically 
alter the pharmacokinetics of these drugs, so it is important to evaluate whether 
a given compound is likely to be a cytochrome P450 substrate. The two main 
isoforms responsible for drug metabolism are P2D6 cytochrome (CYP2D6) and 
P3A4 cytochrome (CYP3A4) [21]. From Table 2 it can be seen that almost all 
ferulic acid derivatives do not affect or inhibit the CYP2D6 and CYP3A4 
enzymes, except the FA20 and FA21 compounds, which can affect the CYP3A4 
enzyme, so it can be predicted that the derivatives tend to be metabolized by the 
P450 enzymes in the body.  
Organic cation transporter 2 (OCT2) is a protein transporter that has a vital 
contribution in renal uptake, disposition, and clearance of drugs and endogenous 
compounds. OCT2 substrates have potential for adverse interactions with 
codirected OCT2 inhibitors. Evaluating the transfer of a candidate compound by 
OCT2 offers useful information regarding not only its clearance but also 
potential contraindications [21]. From Table 2 it can be seen that not all FA 
derivatives affect the OCT2 substrate, so it can be predicted that the derived 
compounds are not OCT2 substrates. 
A steady-state level is reached when the drug is bioavailable and administrated 
at the appropriate dosing rate. Both of these are dependent on drug clearance, 
which can be determined from the total of hepatic (metabolism in the liver and 
biliary clearance) and renal clearance (excretion via the kidneys). The higher the 
CLTOT value of the compound, the faster the excretion process [21]. From 
Table 2 it can be seen that the log CLTOT value of the ferulic acid derivatives 
ranges from -0.070 to 0.800 ml/min/kg and from these values the rate of 
excretion of the compound can be predicted. 
Determining the toxicity of the compound can be done by the Ames toxicity 
test. The Ames test is a method to predict the mutagenic potential of a 
compound using bacteria. A positive test indicates that the compound is 
mutagenic and therefore may act as a carcinogen [21]. From Table 2 it can be 
seen that seven FA derivatives, FA2, FA3, FA4, F9, FA10, FA13, and FA23, 
are predicted to have mutagenic effects. 
Another toxicity test is the hepatotoxicity test. One of the most concerning 
safety aspects in drug development research is drug-induced liver injury, which 
also increases the drug attrition rate. The compound that showed at least one 
pathological or physiological hepatic event was considered hepatotoxic and 
highly related to liver disruption. From Table 2 it can be seen that almost all of 
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the ferulic acid derivatives are not hepatotoxic. Only one compound (FA-21) is 
predicted to induce hepatotoxic effects. 
The potential toxicity of a prospective compound has to be assessed. The acute 
toxicity and relative toxicity of different compounds can be determined from the 
lethal dosage value. To complement the toxicity prediction of ferulic acid 
derivatives there is an acute oral toxicity test for rodents (LD50) and an acute 
toxicity classification of compounds based on the Globally Harmonized System 
(GSH) using the Protox online tool. From Table 2 it can be seen that the 
prediction for the LD50 values of the ferulic acid derivatives range from 300 to 
9600 mg/kg, which means that they are included in toxicity classes from GSH 
Tables 3-6, i.e. the compounds have toxicity indications ranging from ‘has 
harmful effects when swallowed’ to ‘is not toxic’ (Table 2).  
There are three FA derivatives that belong to category 3 GSH (LD50 = > 50 ≤ 
300 mg/kg), i.e. FA20, FA21, FA22, which means that those compounds have 
toxic effects when swallowed, and three compounds belong to category 6 GSH 
(LD50 = > 5000 mg/kg), i.e. FA6, FA7, and FA8, which means that they are not 
toxic. Eight compounds belong to category 5 (LD50 = > 2000 ≤ 5000 mg/kg), 
i.e. FA2, FA10, FA14-19, which means that these compounds have relatively 
low acute toxicity. The other nine compounds belong to category 4, which 
means they are slightly toxic.  
3.3 Physicochemical-ADMET Properties Relationships 
Based on the regression analysis performed between the in silico activities on 
the P2Y12 receptor (MDS, Figure 1) with each physicochemical property, i.e. 
Log P, MR, and Etotal, shown in Table 1, some linear relationships were found 
between the in silico activity on the P2Y12 receptor with each of the 
physicochemical properties, i.e.:  
 MDS ൌ – 2.204 Log P – 0.705 MR – 70.134  (4) 
 (n= 24, Adjust R2= 0.696, F= 27.386, s= 6.98) 
 MDS ൌ – 11.168 Log P – 0.307 𝐸௧௢௧௔௟ – 92.263 (5) 
 (n= 24. Adjust R2= 0.643, F= 18.933, s= 7.92) 
 MDS ൌ – 0.707 MR – 0.331 𝐸௧௢௧௔௟ – 67.985 (6) 
 (n= 24, Adjust R2= 0.735, F= 32.901, s= 6.52) 
 MDS ൌ  0.396 Log P – 0.725 MR – 0.337 𝐸௧௢௧௔௟ – 67.506 (7) 
 (n= 24, Adjust R2= 0.722, F= 20.901, s= 6.68) 
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The equation that showed the highest significance was the relationship between 
MDS and combined MR-Etotal, denoted by Eq. (6) (P < 0.05, adjusted R2 = 
0.735, and F = 32.901). However, the coefficients of each physicochemical 
variable in the regression equations were negative, indicating unfavorable 
relationships. The addition of Log P or Etotal in the regression equations 
containing molar refractivity decreased the significance (F value) and the 
coefficient of each physicochemical variable was still negative.  
The combination of three physicochemical variables in one equation also 
decreased the significance (F value) but gave a positive variable coefficient for 
Log P. These results indicate that the physicochemical properties (Log P, MR, 
and Etotal) will contribute positively to ligand-receptor interactions when 
combined. 
4 Conclusion 
From this study it was concluded that all FA derivatives have good ADMET 
profiles, except three derivatives that are harmful when swallowed. Compound 
FA19 has the greatest activity as antiplatelet agent based on its interaction with 
the P2Y12 receptor. 
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